<div id="readability-page-1"><p>Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at  William Blair raised their FY2029 earnings per share (EPS) estimates for Neumora Therapeutics  in a report released on  Wednesday, August 6th. William Blair analyst M. Minter now expects that the company will earn $1.01 per share for the year, up from their previous estimate of $0.94. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share.</p><p>Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.05. </p><div><p><span></span><span>Get <strong>Neumora Therapeutics</strong> alerts:</span></p></div><p>A number of other research firms also recently issued reports on NMRA. Needham &amp; Company LLC  reiterated a &#34;buy&#34; rating and set a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Mizuho lifted their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, July 16th. One analyst  has rated the stock with a sell rating, five have issued  a hold rating and three have issued  a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $7.14.</p><p><b>Read Our Latest Stock Report on Neumora Therapeutics</b></p><h2>Neumora Therapeutics Stock Down 6.4%</h2><p>Shares of NASDAQ:NMRA traded down $0.11 during mid-day trading on Friday, reaching $1.55. 189,456 shares of the stock were exchanged, compared to its average volume of 2,133,940. The company has a market cap of $249.90 million, a P/E ratio of -0.99 and a beta of 2.91. Neumora Therapeutics has a one year low of $0.61 and a one year high of $17.19. The stock's 50 day simple moving average is $1.23 and its 200-day simple moving average is $1.19. </p><h2>Institutional Trading of Neumora Therapeutics</h2><p>Several institutional investors have recently added to or reduced their stakes in NMRA. Lunate Capital Ltd acquired a new position in  Neumora Therapeutics in the 1st quarter valued at $2,124,000.  Schonfeld Strategic Advisors LLC increased its holdings in  Neumora Therapeutics by 273.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company's stock worth $5,523,000 after purchasing an additional 381,676 shares in the last quarter.  Capital International Investors increased its holdings in  Neumora Therapeutics by 692.1% in the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company's stock worth $39,224,000 after purchasing an additional 3,233,179 shares in the last quarter.  Ameriprise Financial Inc. bought a new stake in shares of  Neumora Therapeutics in the 4th quarter valued at about $1,258,000.  Finally, California State Teachers Retirement System grew its position in shares of  Neumora Therapeutics by 793.5% in the 4th quarter. California State Teachers Retirement System now owns 54,457 shares of the company's stock valued at $577,000 after buying an additional 48,362 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors. </p><h2>About Neumora Therapeutics</h2> (Get Free Report)<p>Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.</p><h2>See Also</h2><ul><li>Five stocks we like better than Neumora Therapeutics</li><li>Conference Calls and Individual Investors</li><li>Tesla Is Balanced on a Knife Edge: Time to Tread Carefully</li><li>How to Evaluate a Stock Before Buying </li><li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li><li>ETF Screener: Uses and Step-by-Step Guide </li><li>DraftKings Posts Record Quarter, Eyes Profitability</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Neumora Therapeutics Right Now?</h2><p>Before you consider Neumora Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.</p><p>While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NMRA

<p>William Blair has raised its FY2029 earnings per share estimate for Neumora Therapeutics (NASDAQ:NMRA) from $0.94 to $1.01. The company recently reported quarterly earnings of ($0.33) per share, exceeding the consensus estimate of ($0.38). Neumora's stock is currently down 6.4%, trading at $1.55, with a market cap of $249.90 million. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average target price of $7.14.</p>

What is William Blair's Estimate for NMRA FY2029 Earnings?